Skip to content

Abstract 14707: Synergistic Cardiovascular Benefits of Combined GLP-1 Receptor Agonists and SGLT2 Inhibitors versus SGLT2 Inhibitor Monotherapy in Patients with Type 2 Diabetes and HFpEF

Nov 2026 · Circulation · 0 citations

Abstract

Background: Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular benefits in type 2 diabetes (T2D). While SGLT2i is a cornerstone therapy for heart failure with preserved ejection fraction (HFpEF), the incremental prognostic benefit of adding a GLP-1RA in this specific, high-risk population remains under-investigated. This real-world study evaluates whether combined dual therapy offers superior cardioprotective outcomes compared to SGLT2i alone in patients with T2D and HFpEF. Methods: Utilizing the TriNetX global federated research network, we identified adult patients diagnosed with T2D and HFpEF. Patients were stratified into two cohorts: combined GLP-1RA and SGLT2i therapy (Cohort 1) versus SGLT2i monotherapy (Cohort 2). Propensity score matching (PSM) at a 1:1 ratio balanced baseline demographics, comorbidities, and critical laboratory values (including eGFR, BMI, HbA1c, and LVEF). The primary endpoints analyzed were All-Cause Mortality (ACM), Major Adverse Cardiovascular Events (MACE), Heart Failure Exacerbation over a one-year follow-up period.Results: Following PSM, each cohort consisted of 21,048 well-matched patients. Baseline characteristics are summarized in Table 1. Dual therapy demonstrated profound superiority across evaluated cardiovascular and mortality endpoints. Compared to SGLT2i monotherapy, the GLP-1RA + SGLT2i combination yielded a 48.1% lower hazard for all-cause mortality (HR: 0.519, 95% CI: 0.479–0.562, p < 0.0001). Furthermore, combination therapy resulted in a 27.1% relative risk reduction in MACE (HR: 0.729, 95% CI: 0.698–0.762, p < 0.0001). The incidence of heart failure exacerbations was also lower in the dual therapy cohort (54.27%) compared to the monotherapy group (57.76%). Conclusion: In a large, propensity-matched cohort of patients with T2D and HFpEF, the addition of GLP-1RA to SGLT2i therapy was associated with significantly superior reductions in all-cause mortality, MACE, and heart failure exacerbations compared to SGLT2i monotherapy alone. These real-world data strongly support the early synergistic use of dual incretin and SGLT2 inhibition to improve survival and reduce acute decompensation in HFpEF.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.